WO2023031881 - COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME
National phase entry:
Publication Number
WO/2023/031881
Publication Date
09.03.2023
International Application No.
PCT/IB2022/058286
International Filing Date
02.09.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME
[French]
COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU SYNDROME DU QT LONG
Applicants **
UNIVERSITY OF BERN
Inventors
LI, Jin
Priority Data
63/240,494
03.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2328 | |
| EPO | Filing, Examination, Granting | 11361 | |
| Japan | Filing, Examination, Granting | 2325 | |
| South Korea | Filing, Examination, Granting | 2371 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
24,925
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides anti-KCNQ1 monoclonal antibodies and their use in treating long QT syndrome (LQTS).[French]
La présente invention concerne des anticorps monoclonaux anti-KCNQ1 et leur utilisation dans le traitement du syndrome du QT long (LQTS).